Serum Institute of India applies to DCGI to manufacture Covid vaccine Sputnik V
The Pune-based firm has also sought approval for test analysis and examination.
''The Serum Institute of India (SII) put up an application to the Drugs Controller General of India (DCGI) on Wednesday seeking permission to manufacture the COVID-19 vaccine, Sputnik V, in India,'' a source said.
The SII has already told the government that it will be able to manufacture and supply 10 crore Covishield doses in June, while it is also manufacturing the Novavax vaccine, the regulatory clearance for which is awaited from the United States.
The vaccine was given emergency use authorization (EUA) by the DCGI in April.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)